Indivior Pharmaceuticals, Inc. — Earnings Quality Grade F
INDV · Healthcare
Major red flags
Screening Summary
Management Signals
Source: SEC EDGAR 8-K Item 5.02, with exhibit links when available
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 75 days, change -4 days YoY
AR growth -0.4% vs revenue growth 4.3%
Revenue 4.3%, CFFO -175.0%. Cash follows revenue
Expense Quality
Inventory -12.9% vs COGS 6.5%. Normal
CapEx growth 116.1% is >2x revenue growth 4.3%
SG&A/Gross Profit = 63.8%. Normal
Gross margin 80.1%, change -0.4pp. Stable
Cash Flow Quality
CFFO/NI = -0.13. Only -13% of profit backed by cash
FCF is negative ($-0.1B)
Accruals ratio = 19.7%. Exceeds 10%
Cash $0.2B covers 56% of debt $0.4B
Balance Sheet Health
Goodwill+Intangibles $0.0B = -2% of equity. Manageable
Debt/EBITDA = 1.2x. Healthy
Other assets -30.8% vs revenue 4.3%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 2/3 years
Goodwill+Intangibles change -71% YoY. Normal
Manipulation Score
M-Score = -1.43 (> -1.78). LIKELY MANIPULATOR
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25